Erasca securities class action over ERAS-0015
Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Aug 10, 2026
The disclosures and subsequent class action have severely damaged investor confidence in Erasca, leading to a cumulative stock decline of over 50% in two days. The litigation and alleged patent issues create significant legal and financial uncertainty for the company, potentially affecting its ability to advance ERAS-0015 and raising concerns about its intellectual property position.
Erasca faces a federal securities class action alleging that it and its executives violated securities laws by making false and misleading statements about its drug candidate ERAS-0015. The complaint claims Erasca's preclinical data was based on improper comparisons to Revolution Medicines' compound RMC-6236, placing Erasca at risk of patent infringement and trade secret misappropriation. On April 27, 2026, Erasca disclosed receipt of a letter from Revolution Medicines' counsel alleging patent infringement (U.S. Patent No. 12,409,225) and improper data comparisons, causing its stock to fall 10.9%. Later that day, Erasca reported preliminary Phase 1 data revealing a patient death classified as a Grade 3 treatment-related adverse event, and acknowledged that comparisons to other candidates were not based on head-to-head trials. This caused an additional 45% drop, with shares falling from $21.49 to $9.90 over two days. Faruqi & Faruqi, LLP is investigating and reminds investors of the August 10, 2026 lead plaintiff deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard